Xenetic Biosciences, Inc. (Nasdaq: XBIO) to Ring The Nasdaq Stock Market Opening Bell
March 29 2017 - 10:56AM
What: Xenetic Biosciences,
Inc. (Nasdaq:XBIO), a clinical-stage biopharmaceutical company
focused on the discovery, research and development of
next-generation biologic drugs and novel orphan oncology
therapeutics, will visit the Nasdaq MarketSite in Times Square.
In honor of the occasion, M Scott Maguire, Chief
Executive Officer will ring the Opening Bell.
Where:Nasdaq MarketSite – 4 Times
Square – 43rd & Broadway – Broadcast Studio
When:Thursday, March 30, 2017 –
9:15 a.m. to 9:30 a.m. ET
Xenetic Biosciences Media
Contact:Jenene ThomasJenene Thomas Communications,
LLC(908) 938-1475 jenene@jenenethomascommunications.com
Nasdaq MarketSite:Emily Pan(646)
441-5120 emily.pan@nasdaq.com
Feed Information:Fiber Line
(Encompass Waterfront): 4463
Gal 3C/06C 95.05 degrees West 18 mhz Lower DL 3811
Vertical FEC 3/4 SR 13.235 DR 18.295411 MOD 4:2:0 DVBS QPSK
Social Media:For multimedia
features such as exclusive content, photo postings, status updates
and video of bell ceremonies, please visit our Facebook
page:http://www.facebook.com/NASDAQ.
For photos from ceremonies and events, please visit
our Instagram page:http://instagram.com/nasdaq
For livestream of ceremonies and events, please
visit our YouTube page:http://www.youtube.com/nasdaq/live
For news tweets, please visit our Twitter
page:http://twitter.com/nasdaq
For exciting viral content and ceremony photos,
please visit our Tumblr page:http://nasdaq.tumblr.com/
Webcast: A live stream of the
Nasdaq Opening Bell will be available at:
https://new.livestream.com/nasdaq/live or
http://www.nasdaq.com/about/marketsitetowervideo.asx
Photos: To obtain a hi-resolution
photograph of the Market Open, please go to
http://business.nasdaq.com/discover/market-bell-ceremonies and
click on the market open of your choice.
About Xenetic BiosciencesXenetic
Biosciences, Inc. is a clinical-stage biopharmaceutical
company focused on the discovery, research and development of
next-generation biologic drugs and novel orphan oncology
therapeutics. Xenetic's proprietary drug development platforms
include PolyXen™, which enables next generation biologic drugs by
improving their half-life and other pharmacological properties.
Xenetic's lead investigational product candidates include oncology
therapeutic XBIO-101 (sodium cridanimod) for the treatment of
progesterone resistant endometrial cancer (EC), and a
polysialylated form of erythropoietin for the treatment of anemia
in pre-dialysis patients with chronic kidney disease.
Xenetic is also working together with Shire plc
(formerly Baxalta, Baxter Incorporated and Baxter Healthcare)
to develop a novel series of polysialylated blood coagulation
factors, including a next generation Factor VIII. This
collaboration relies on Xenetic's PolyXen technology to conjugate
polysialic acid (“PSA”) to therapeutic blood-clotting factors, with
the goal of improving the pharmacokinetic profile and extending the
active life of these biologic molecules. Shire is a significant
stockholder of the Company, having invested $10 million in the
Company during 2014. The agreement is an exclusive research,
development and license agreement which grants Shire a worldwide,
exclusive, royalty-bearing license to Xenetic's PSA patented and
proprietary technology in combination with Shire's proprietary
molecules designed for the treatment of blood and bleeding
disorders. Under the agreement, Xenetic may receive regulatory and
sales target payments for total potential milestone receipts of up
to $100 million plus royalties on sales.
Xenetic is also developing a broad pipeline of
clinical candidates for next generation biologics and novel
oncology therapeutics in a number of orphan disease indications.
For more information, please visit the company's website
at www.xeneticbio.com and connect
on Twitter, LinkedIn, Facebook and Google+.
About NasdaqNasdaq (Nasdaq:NDAQ)
is a leading provider of trading, clearing, exchange technology,
listing, information and public company services across six
continents. Through its diverse portfolio of solutions, Nasdaq
enables clients to plan, optimize and execute their business vision
with confidence, using proven technologies that provide
transparency and insight for navigating today's global capital
markets. As the creator of the world's first electronic stock
market, its technology powers more than 85 marketplaces in 50
countries, and 1 in 10 of the world's securities transactions.
Nasdaq is home to approximately 3,800 listed companies with a
market value of $10.1 trillion and nearly 18,000 corporate clients.
To learn more, visit: business.nasdaq.com.
-NDAQA-
Nasdaq (NASDAQ:NDAQ)
Historical Stock Chart
From Aug 2024 to Sep 2024
Nasdaq (NASDAQ:NDAQ)
Historical Stock Chart
From Sep 2023 to Sep 2024